Finance

Lists
Why is CGEM down ၃.၈၂%?
Dive Deeper
CGEM:NASDAQ
Cullinan Therapeutics Inc
၁၅.၆၃ US$
-၃.၈၂%
(-၀.၆၂) 1D
၁၅.၆၃ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၇, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGEM...
Open
၁၅.၉၅ US$
High
၁၆.၄၆ US$
Low
၁၅.၄၇ US$
Mkt. cap
၁၀၀.၅၉ ဋေ
Avg. vol.
၁.၁၄ သန်း
Volume
၈.၀၈ သိန်း
52-wk high
၂၃.၁၉ US$
52-wk low
၅.၈၆ US$
EPS
-၃.၄၁ US$
Beta
-၀.၀၅
Shares outstanding
၆.၄၄ ကုဋေ
No. of employees
၁၀၉
Open
၁၅.၉၅ US$
High
၁၆.၄၆ US$
Low
၁၅.၄၇ US$
Mkt. cap
၁၀၀.၅၉ ဋေ
Avg. vol.
၁.၁၄ သန်း
Volume
၈.၀၈ သိန်း
52-wk high
၂၃.၁၉ US$
52-wk low
၅.၈၆ US$
EPS
-၃.၄၁ US$
Beta
-၀.၀၅
Shares outstanding
၆.၄၄ ကုဋေ
No. of employees
၁၀၉
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၅၁ မိနစ်
How FDA Filing Progress Will Impact Cullinan Therapeutics Stock
About Cullinan Therapeutics Inc
CEO-
Employees၁၀၉
Founded၂၀၁၆
Headquarters-
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to CGEM in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CGEM in the last 3 months.
Highest
Current ၁၅.၆၃ US$
၄၇.၀၀ US$ (+၂၀၀.၇၀%)
Average
၃၅.၇၀ US$ (+၁၂၈.၄၁%)
Lowest
၂၇.၀၀ US$ (+၇၂.၇၄%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Maintained
၄၂.၀၀ US$
+၁၆၈.၇%
10/07/2026
Samantha Semenkow
Citi
Buy
Maintained
၃၃.၀၀ US$
+၁၁၁.၁%
10/06/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
10/02/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
၃၅.၀၀ US$
+၁၂၃.၉%
10/02/2026
Julian Harrison
BTIG
Buy
Maintained
၄၀.၀၀ US$
+၁၅၅.၉%
10/01/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
09/24/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
၃၉.၀၀ US$
+၁၄၉.၅%
09/16/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
၃၀.၀၀ US$
+၉၁.၉%
09/15/2026
Boris Peaker
JonesTrading
Buy
Maintained
၃၆.၀၀ US$
+၁၃၀.၃%
09/14/2026
David Dai
UBS
Buy
Maintained
၂၇.၀၀ US$
+၇၂.၇%
08/17/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
၂၈.၀၀ US$
+၇၉.၁%
08/13/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
၄၇.၀၀ US$
+၂၀၀.၇%
08/14/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
06/10/2026
Soumit Roy
JonesTrading
Buy
Maintained
၃၆.၀၀ US$
+၁၃၀.၃%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
၃၀.၀၀ US$
+၉၁.၉%
03/10/2026
Last report
၂၀၂၆ ဩ ၆
Fiscal period
Q2 2026
EPS / Est. (USD)
-၀.၈၁ US$ / -၀.၈၅ US$
+၄.၈၅%beat
Revenue / Est. (USD)
- / ၀.၀၀
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၄.၂၀ ကုဋေ
၄.၂၉ ကုဋေ
၄.၂၁ ကုဋေ
၄.၄၄ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၃၆ ကုဋေ
၁.၂၃ ကုဋေ
၁.၁၆ ကုဋေ
၁.၂၈ ကုဋေ
Operating expense
၅.၅၆ ကုဋေ
၅.၅၃ ကုဋေ
၅.၃၇ ကုဋေ
၅.၇၃ ကုဋေ
Total operating expenses
၅.၅၆ ကုဋေ
၅.၅၃ ကုဋေ
၅.၃၇ ကုဋေ
၅.၇၃ ကုဋေ
Operating income
-၅.၅၆ ကုဋေ
-၅.၅၃ ကုဋေ
-၅.၃၇ ကုဋေ
-၅.၇၃ ကုဋေ
Other non operating income
-၁.၀၈ သိန်း
-၆.၉၀ သောင်း
-၆.၂၀ သောင်း
-၉.၈၀ သောင်း
EBT including unusual items
-၅.၀၆ ကုဋေ
-၅.၀၇ ကုဋေ
-၄.၉၇ ကုဋေ
-၅.၃၇ ကုဋေ
EBT excluding unusual items
-၅.၀၆ ကုဋေ
-၅.၀၇ ကုဋေ
-၄.၉၇ ကုဋေ
-၅.၃၇ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၅.၀၆ ကုဋေ
-၅.၀၇ ကုဋေ
-၄.၉၇ ကုဋေ
-၅.၃၇ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၇၇
-၀.၇၇
-၀.၇၅
-၀.၈၁
Interest and investment income
၅.၀၉ သန်း
၄.၆၂ သန်း
၄.၁၀ သန်း
၃.၆၅ သန်း
Interest expense
-
-
-
-
Net interest expenses
၅.၀၉ သန်း
၄.၆၂ သန်း
၄.၁၀ သန်း
၃.၆၅ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၅.၅၅ ကုဋေ
-၅.၅၂ ကုဋေ
-၅.၃၆ ကုဋေ
-၅.၇၂ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ